Type 1 and Type 2 diabetes both involve dysfunction of insulin-producing beta cells — Type 1 through autoimmune destruction, Type 2 through insulin resistance and beta-cell exhaustion. Stem-cell research targets both: placental mesenchymal stem cells and fetal-derived stem cells are studied for their potential to differentiate toward insulin-producing cells, support pancreatic tissue, and dampen autoimmunity. In Type 1 the immune-modulating properties may restrain beta-cell attack; in Type 2 the aim is to ease insulin resistance and support residual reserve. Translating stem-cell-derived beta cells into safe, scalable, durable treatment remains a major unsolved scientific challenge, and all current clinical work is early-stage.
Two hundred thirty-six registered trials and 26 recruiting studies address stem-cell therapy in diabetes — the largest trial landscape among the conditions here. Small cohorts report modest improvements in insulin secretion and HbA1c, but quality is heterogeneous and controls are often absent. Some report temporary reductions in insulin requirement; durability beyond 12 months is poorly documented. No trial has produced insulin independence in Type 1, and sustained insulin-free control in Type 2 is rare.
Indicative European costs are roughly €4,000–€8,000 per course, reflecting cell expansion, purity testing, and frequently multiple infusions. Type 1 protocols may add immune-monitoring; Type 2 protocols often bundle metabolic assessment and follow-up. For context, insulin and monitoring supplies cost roughly €100–€300 monthly and are proven — the stem-cell figure is indicative and unproven.
Cell therapy for Diabetes (Type 1 & 2) is offered as an individualised, physician-led programme. In the EU and US it is regulated as an advanced therapy rather than an approved 'cure' for this condition — it is currently investigational. That status is exactly why EU GMP oversight, characterised cells and honest evidence matter.
Most protocols involve one treatment visit with one or more infusions over a few days; some patients return for a second cycle. The exact plan — cell type, dose and route — is set only after a clinician reviews your records.
Eligibility depends on condition stage, age and overall health. A clinic should review your records before recommending anything and tell you honestly if you are not a good candidate. Our candidacy self-check gives an indicative read in 60 seconds.
An indicative Diabetes (Type 1 & 2) programme is €3,000–€8,000 for treatment (it varies by procedure). Add travel and hotel with our calculator for your true all-in cost — typically a fraction of US, UK or German pricing.
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
← Back to Diabetes (Type 1 & 2) overview · Diabetes (Type 1 & 2) cost →
Medicina regenerativa certificada GMP en el corazón de la UE — desde 3.000–8.000 €, una fracción de los precios de EE. UU. o Alemania. Protocolos personalizados para pacientes de más de 50 países.
Evaluación médica gratuita